ATE553761T1 - Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür - Google Patents

Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür

Info

Publication number
ATE553761T1
ATE553761T1 AT05854594T AT05854594T ATE553761T1 AT E553761 T1 ATE553761 T1 AT E553761T1 AT 05854594 T AT05854594 T AT 05854594T AT 05854594 T AT05854594 T AT 05854594T AT E553761 T1 ATE553761 T1 AT E553761T1
Authority
AT
Austria
Prior art keywords
methods
citrate salt
crystalline
discussed
application
Prior art date
Application number
AT05854594T
Other languages
German (de)
English (en)
Inventor
Carole Neves
Aurelia Chevalier
Pascal Billot
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE553761T1 publication Critical patent/ATE553761T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT05854594T 2004-12-17 2005-12-19 Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür ATE553761T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63721304P 2004-12-17 2004-12-17
PCT/US2005/045915 WO2006066200A2 (en) 2004-12-17 2005-12-19 Solid forms of a chemokine receptor antagonist and methods of use thereof

Publications (1)

Publication Number Publication Date
ATE553761T1 true ATE553761T1 (de) 2012-05-15

Family

ID=36588631

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05854594T ATE553761T1 (de) 2004-12-17 2005-12-19 Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür

Country Status (9)

Country Link
US (2) US7960549B2 (https=)
EP (1) EP1841429B1 (https=)
JP (3) JP5308030B2 (https=)
CN (1) CN101119725B (https=)
AT (1) ATE553761T1 (https=)
AU (1) AU2005316340B2 (https=)
CA (1) CA2590157C (https=)
ES (1) ES2386029T3 (https=)
WO (1) WO2006066200A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12492211B2 (en) * 2019-11-29 2025-12-09 Sunshine Lake Pharma Co., Ltd. Crystalline form of nitrogen-containing tricyclic compound and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910144A (pt) 1998-01-21 2002-04-02 Millennium Pharm Inc Antagonistas de receptores de quimiocinas e seu uso
US6613905B1 (en) 1998-01-21 2003-09-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6509346B2 (en) 1998-01-21 2003-01-21 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6433165B1 (en) 1998-01-21 2002-08-13 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US6503926B2 (en) 1998-09-04 2003-01-07 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7271176B2 (en) 1998-09-04 2007-09-18 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use thereof
US20020169155A1 (en) 1998-09-04 2002-11-14 Millennium Pharmaceuticals, Inc. Chemokine receptor anagonists and methods of use therefor
US6288083B1 (en) 1998-09-04 2001-09-11 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
CA2343536A1 (en) 1998-09-04 2000-03-16 Yoshisuke Nakasato Chemokine receptor antagonists and methods of use therefor
MXPA04004826A (es) * 1998-09-04 2004-08-11 Millenium Pharmaceuticals Inc Antagonista del receptor de quimioquinas y metodos para su uso.
EP1204664A1 (en) 1999-07-28 2002-05-15 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
US7541365B2 (en) 2001-11-21 2009-06-02 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
TWI291467B (en) 2002-11-13 2007-12-21 Millennium Pharm Inc CCR1 antagonists and methods of use therefor

Also Published As

Publication number Publication date
US7960549B2 (en) 2011-06-14
CA2590157C (en) 2013-11-05
US8481737B2 (en) 2013-07-09
WO2006066200A3 (en) 2007-01-25
AU2005316340A1 (en) 2006-06-22
EP1841429A2 (en) 2007-10-10
CN101119725A (zh) 2008-02-06
CA2590157A1 (en) 2006-06-22
EP1841429B1 (en) 2012-04-18
JP2008524253A (ja) 2008-07-10
JP5308030B2 (ja) 2013-10-09
ES2386029T3 (es) 2012-08-07
US20120065223A1 (en) 2012-03-15
CN101119725B (zh) 2013-04-17
JP2015057445A (ja) 2015-03-26
US20070010545A1 (en) 2007-01-11
HK1109350A1 (en) 2008-06-06
JP2012211197A (ja) 2012-11-01
WO2006066200A2 (en) 2006-06-22
AU2005316340B2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
WO2007058602A3 (en) Novel 2-amino-imidazole-4-one compounds and their use in the manufacture of a medicament to be used in the treatment of cognitive impairment, alzheimer’s disease, neurodegeneration and dementia.
NZ617196A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
DE602006018961D1 (de) KRISTALLINE FORMEN VON 1-CHLORO-4-(ß-D-GLUCOPYRANOS-1-YL)-2-(4-ETHYNYL-BENZYL)-BENZOL, ZUBEREITUNGSVERFAHREN DAFÜR UND DESSEN VERWENDUNG ZUR ARZNEIMITTELHERSTELLUNG
WO2005014533A3 (en) Aryl and heteroaryl compounds, compositions, and methods of use
WO2005016261A3 (en) Aripiprazole and haloperidol pamoate salts
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
BRPI0519124A2 (pt) composto, mÉtodo para tratar, prevenir ou melhorar obesidade e doenÇas relacionadas e/ou sintomas das mesmas, composiÇço farmacÊutica, uso de composto, e, combinaÇço
TW200606162A (en) Pyrazolopyridine derivatives
GEP20084417B (en) Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
UA92584C2 (ru) Применение мелоксикама для лечения респираторных заболеваний у свиней
BRPI0407662A (pt) derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas
WO2006074265A3 (en) Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders
EP2543384A3 (en) Treatment of conditions involving demyelination
IL175259A0 (en) Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof
WO2004082584A3 (en) 5ht2c receptor antagonists in the treatment of schizophrenia
RU2008127882A (ru) Лечение пищевода барретта
EP4566667A3 (en) Treatment of cardiometabolic disease with inhibitors of type i interferon signalling
MX2010005545A (es) Oxazolidinonas para el tratamiento y/o profilaxis de la insuficiencia cardiaca.
ATE553761T1 (de) Solide formen eines chemokin-rezeptorantagonisten und anwendungsverfahren dafür
EP2272850A3 (en) Process for purifying staurosporine
IL183104A0 (en) Method for production of candesartan
UA86399C2 (ru) Применение 2,5 дигидроксибензолсульфоновой кислоты для изготовления лекарства, которые применяют для лечения болезней, зависимых от ангиогенеза
MX2007007472A (es) Derivados de triazolona, tetrazolona e imidazolona para uso como antagonista del adrenorreceptor alfa-2c.
ME00935B (me) Upotreba 4-ciklopropilmetoksi-<i>n</i>-(3,5-dihlor0-1- 0ksido- piridin-4-il)-5-(metoksi)piridin-2- karboksamida za liječenje motoričkih poremećaja povezanih sa parkinsonovom bolešću